Liver Transplantation for Cancer: The Future of Transplant Oncology
A special issue of Current Oncology (ISSN 1718-7729).
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 3331
Special Issue Editor
Interests: liver; transplantation; hepatocellular carcinoma; cholangiocellular carcinoma; surgery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Liver transplantation (LT) for hepatocellular carcinoma (HCC) is a treatment that includes the underlying cirrhosis; theoretically, there is no better treatment. Many studies showed that selected patients with HCC can have improved outcomes after LT. Recently, other hepatobiliary malignancies, such as unresectable perihilar cholangiocarcinoma or liver metastasis for colorectal cancer, have been treated by LT with significant improved outcomes. The concept of such cancer treatment is defined as “transplant oncology”. On the other hand, there are some cautious views that LT for non-HCC malignancies including neuroendocrine tumors should be performed only in high-volume centers under strict selection criteria due to the current shortage of available organs. With this Special Issue, we aim to discuss the selection criteria, pre-LT treatment, appropriate immunosuppressive regimen, and strategies for the follow-up of LT for hepatobiliary malignancies to establish the concept of transplant oncology.
You may choose our Joint Special Issue in Cancers.
Prof. Dr. Tomoharu Yoshizumi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
